Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 27,464,314 shares, a decrease of 7.6% from the January 12th total of 29,723,183 shares. Based on an average daily trading volume, of 3,192,320 shares, the days-to-cover ratio is presently 8.6 days. Currently, 17.0% of the company’s shares are short sold.
In other Amicus Therapeutics news, COO Bradley L. Campbell sold 32,500 shares of the stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $15.92, for a total transaction of $517,400.00. Following the completion of the sale, the chief operating officer now owns 186,600 shares of the company’s stock, valued at approximately $2,970,672. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Daphne Quimi sold 8,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total transaction of $117,760.00. Following the sale, the senior vice president now directly owns 62,676 shares of the company’s stock, valued at approximately $922,590.72. The disclosure for this sale can be found here. Insiders sold 250,390 shares of company stock valued at $3,620,581 in the last ninety days. 3.40% of the stock is currently owned by insiders.
Several hedge funds have recently made changes to their positions in FOLD. Eagle Asset Management Inc. acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter worth approximately $40,450,000. Jennison Associates LLC grew its position in shares of Amicus Therapeutics by 9.4% during the 3rd quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock worth $147,362,000 after buying an additional 838,267 shares during the period. Allianz Asset Management GmbH acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter worth approximately $11,381,000. Perceptive Advisors LLC grew its position in shares of Amicus Therapeutics by 3.4% during the 3rd quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock worth $269,760,000 after buying an additional 591,925 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Amicus Therapeutics by 5.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock worth $91,821,000 after buying an additional 430,486 shares during the period.
Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at $14.72 on Friday. The company has a market cap of $2,450.00, a P/E ratio of -8.04 and a beta of 1.45. Amicus Therapeutics has a 52-week low of $5.87 and a 52-week high of $17.40. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.